Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Clinical shorts

CMAJ Editors
CMAJ April 19, 2011 183 (7) 824; DOI: https://doi.org/10.1503/cmaj.110485
CMAJ Editors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Drug treatment for generalized anxiety disorder

Selective serotonin reuptake inhibitors are the most effective drug treatment option for patients with generalized anxiety disorder. This is the conclusion of a systematic review and meta-analysis that included 27 randomized controlled trials of adults receiving pharmacologic treatment for generalized anxiety disorder. Three primary outcomes were considered for the nine drugs compared in the study: response and remission as measures of efficacy and withdrawals as a measure of tolerability. In probabilistic analysis, fluoxetine was ranked first for response and remission, whereas sertraline was associated with the lowest percentage of withdrawals. The meta-analysis was limited by the small number of trials comparing one drug with another; placebo was often the common comparator. See BMJ 2011;342:d1199 doi:10.1136/bmj.d1199.

Olmesartan and microalbuminuria

Would treatment with an angiotensin-receptor blocker such as olmesartan delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria? Yes it would, but it could also increase the number of fatal cardiovascular events. This is the finding of a placebo-controlled randomized controlled trial involving 4447 patients who received olmesartan or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers) were used as needed to lower blood pressure with excellent control in both groups of patients. Microalbuminuria developed in 8.2% of the patients in the olmesartan group and in 9.8% of patients in the placebo group, and the time to the onset of microalbuminuria was increased by 23% with olmesartan (hazard ratio [HR] 0.77; 95% confidence interval [CI], 0.63 to 0.94; p = 0.01). Fifteen patients taking olmesartan had fatal cardiovascular events (0.7%), as compared with three patients who were given placebos (0.1%) (p = 0.01). See N Engl J Med 2011;364:907–17.

Early versus delayed percutaneous tracheotomy

When compared with prolonged ventilation, possibly followed by late tracheotomy, early percutaneous tracheotomy did not reduce mortality, infectious complication rates, duration of mechanical ventilation and length of hospital stay in patients who needed prolonged mechanical ventilation after cardiac surgery. It did, however, result in less sedation, more comfort and earlier ambulation. This is what researchers found in their prospective randomized controlled trial that involved 216 patients who still required mechanical ventilation four days after cardiac surgery. They randomized patients to have tracheotomy either on the fourth day or two weeks after intubation. This study was done in a single centre, limiting the ability to generalize its results. Moreover, only 27% of patients in the prolonged intubation group had late tracheotomy, and this might have diluted the overall early tracheotomy effect on the entire cohort. See Ann Inter Med 2011;154:373–83.

Irbesartan in patients with atrial fibrillation

Irbesartan, an angiotensin-receptor blocker, did not reduce cardiovascular events in patients with atrial fibrillation in a randomized, double-blind, placebo-controlled trial. Over 9000 patients with a history of risk factors for stroke and a systolic blood pressure of at least 110 mm Hg were enrolled and followed for a mean of 4.1 years. The trial used complicated outcomes. The first co-primary outcome was stroke, myocardial infarction or death from vascular causes; the second coprimary outcome was the first composite coprimary outcome plus admission to hospital for heart failure. The first coprimary outcome occurred at a rate of 5.4% per 100 person-years in both groups (HR 0.99; 95% CI 0.91–1.08; p = 0.85), The second coprimary outcome occurred at a rate of 7.3% per 100 person-years among patients receiving irbesartan and 7.7% per 100 person-years among patients receiving placebo (HR 0.94; 95% CI 0.87–1.02; p = 0.12). See N Engl J Med 2011;364:928–38.

Radial artery grafts in coronary artery bypass surgery

The success of coronary artery bypass surgery largely depends on the long-term patency of the arterial or venous grafts used. With good results in using left internal mammary artery grafts to the left anterior descending coronary artery, surgeons have been looking at the use of other arterial grafts. In this randomized controlled trial, 757 participants undergoing first-time elective coronary artery bypass surgery had grafting of the left anterior descending coronary artery using the left internal mammary artery when possible; they were then randomized to radial artery or saphenous vein grafting for the best remaining recipient artery. At one year, there was no significant difference in study graft patency assessed by angiography between the two groups (89% for both groups), nor were there significant differences in the rates of myocardial infarction, stroke, repeat revascularization or death. The authors acknowledge, however, that there was more disease (e.g. partial stenosis) in the radial artery grafts at one week and at one year, despite patency. What will happen with the grafts in the longer term is unclear. All but six participants were men. See JAMA 2011;305: 167–74.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 183 (7)
CMAJ
Vol. 183, Issue 7
19 Apr 2011
  • Table of Contents
  • Index by author
  • CMAJ 100th Anniversary Tributes

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical shorts
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinical shorts
CMAJ Editors
CMAJ Apr 2011, 183 (7) 824; DOI: 10.1503/cmaj.110485

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Clinical shorts
CMAJ Editors
CMAJ Apr 2011, 183 (7) 824; DOI: 10.1503/cmaj.110485
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Drug treatment for generalized anxiety disorder
    • Olmesartan and microalbuminuria
    • Early versus delayed percutaneous tracheotomy
    • Irbesartan in patients with atrial fibrillation
    • Radial artery grafts in coronary artery bypass surgery
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire